Triple-negative breast cancer (TNBC) accounts for 15–20% of all breast cancer cases and is characterized by the lack of estrogen receptor (ER), progesterone receptor (PR), and HER2 expression [12,13]. This evidence concerns the gene ESR1 and triple-negative breast carcinoma.